시장보고서
상품코드
1149318

세계의 RWE(Real World Evidence) 솔루션 시장 : 구성 요소별(서비스, 이종 데이터 세트(청구, 임상, 약국, 환자)), 용도별(종양, 순환기, 신경, 면역), 최종 사용자별(제약, 의료 기술, 의료비 지불자, 의료 제공자) 예측(2027년)

Real World Evidence Solutions Market by Component (Services, Disparate Data Sets, (Claims, Clinical, Pharmacy, Patient), Application (Oncology, Cardiovascular, Neurology, Immunology), End User(Pharma, Medtech, Payers, Providers) -Global Forecast -2027

발행일: | 리서치사: MarketsandMarkets | 페이지 정보: 영문 266 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

전 세계의 RWE(Real World Evidence Solution) 시장 규모는 2022년 15억 달러에서 2027년 29억 달러에 이를 것으로 예측되며 예측 기간 동안 15.2% CAGR로 예측됩니다. 노년 인구 증가와 그에 따른만성 질환 유병률 증가, 규제 기관 지원은 도시 성장을 촉진하고 있습니다. 또한 전자 의료 기록(EHR) 및 집단 건강 관리와 같은 솔루션은 과중 노동이 되는 의료 제공 시스템 부담을 줄이기 위해 여러 국가에서 채택되었습니다. 디지털 건강 솔루션을 통해 생성되는 엄청난 양의 RWD는 임상 결과를 더 잘 이해하는 데 도움이 됩니다. 그 결과, RWE 솔루션 채용은 세계적으로 증가하고 있습니다.

목차

제1장 소개

제2장 조사 방법

제3장 주요 요약

제4장 중요 고찰

제5장 시장 주요 요약

  • 소개
  • 시장 역학

제6장 업계 고찰

  • 산업 동향
    • 웨어러블 디바이스 새로운 역할
    • 소셜 미디어 소스 RWE
    • 제약 업계 전체에서 RWD와 RWE 사용 증가
    • 내제형·외주형 RWE 분석 어프로치
    • RWD 관리에 인공 지능(AI) 통합
  • 리얼월드 데이터 소스
  • 에코시스템 분석
  • 포터의 5가지 경쟁요인 분석
  • 가격 분석
  • 기술분석
  • 규제기관, 정부, 기타 조직
  • 특허분석
  • 주요 회의와 이벤트(2022-2023년)
  • 주요 이해관계자와 구매기준

제7장 RWE 솔루션 시장 : 컴포넌트별

  • 소개
  • 서비스
  • 데이터 세트
    • 이종 데이터 세트
    • 일체형 데이터 세트

제8장 RWE 솔루션 시장 : 용도별

  • 소개
  • 의약품 개발·승인
    • 종양
    • 순환기 질환
    • 신경질환
    • 면역 질환
    • 기타 치료 분야
  • 의료기기 개발·승인
  • 시판 후 조사
  • 시장 접근 및 상환/보상 범위 결정
  • 임상·규제에 관한 의사결정

제9장 RWE 솔루션 시장 : 최종 사용자별

  • 소개
  • 제약기업·의료기기기업
  • 의료비 지불자
  • 의료 제공자
  • 기타 최종 사용자

제10장 RWE 솔루션 시장 : 지역별

  • 소개
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 기타 유럽 국가
  • 아시아태평양 지역
    • 일본
    • 중국
    • 인도
    • 기타 아시아태평양 국가
  • 라틴아메리카
  • 중동·아프리카

제11장 경쟁 상황

  • 주요 요약
  • 주요 기업이 채용한 전략/유력 기업
  • 주요 기업 수익 점유율 분석
  • 시장 랭킹 분석
  • 경쟁 벤치마킹
  • 기업 발자국
    • 기업 최종 사용자, 풋 프린트
    • 기업 제품 발자국
    • 기업 지역 풋프린트
  • 기업 평가 쿼드런트
  • 신흥기업/중소기업용 기업평가 쿼드런트
  • 경쟁 시나리오
    • FDA 승인/서비스 강화
    • 자본거래
    • 기타 개발

제12장 기업 프로필

  • 주요 기업
    • IQVIA HOLDINGS INC.
    • IBM CORPORATION(IBM)
    • OPTUM INC.(THE UNITED HEALTH GROUP, INC. 자회사)
    • ICON PLC.
    • SYNEOS HEALTH, INC.
    • PAREXEL INTERNATIONAL CORPORATION
    • THERMO FISHER SCIENTIFIC INC.
    • LABCORP HOLDINGS
    • ORACLE CORPORATION
    • ELEVANCE HEALTH
    • SAS INSTITUTE
    • AETION INC.
    • TRINETX LLC
    • TRINITY LIFE SCIENCES
    • PERKINELMER INC.
    • COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION
    • CLINIGEN
    • CEGEDIM HEALTH DATA
    • VERANTOS INC.
    • MEDPACE HOLDINGS INC.
  • 기타 기업
    • HEALTHVERITY INC.
    • DATAVANT
    • SYAPSE INC.
    • TEMPUS LABS INC.
    • FLATIRON HEALTH

제13장 부록

NJH 22.11.15

The global RWE Solutions market is projected to reach USD 2.9 Billion by 2027 from USD 1.5 Billion in 2022, at a CAGR of 15.2% during the forecast period. Rise in the geriatric population and the subsequent increase in the prevalence of chronic diseases and support from regulatory bodies for the use of RWE solutions is driving the growth of the RWE solutions market. Given the large pool of geriatric individuals requiring health and long-term care services, the healthcare cost per person is expected to increase in many countries. Solutions such as EHR and population health management are being employed to reduce the burden on the overworked healthcare delivery systems in several countries. The significant amount of RWD that is being generated through digital health solutions is helping in better understanding clinical outcomes. As a result, the adoption of RWE solutions is increasing globally.

Pharmacy data is expected to witness the fastest growth during the forecast period

Based on component, the RWE solutions market is segmented into data sets and services. In 2021, services segment dominated the RWE solutions market owing to the availability of a large volume of healthcare data on the basis of which advanced analytics and consulting services can be offered. The data sets segment has been further segmented into disparate data sets and integrated data sets. The disparate data sets is further segmented into clinical settings data, claims data, pharmacy data, patient-powered data, and other data sets . The pharmacy data sets segment is expected to witness fastes growth rate during the forecast period owing to rising efforts to decrease medication nonadherence and the increasing adoption of e-prescribing systems.

"Drug development and approvals dominates the RWE solutions market in 2021"

Based on the application, the RWE solutions market is broadly categorized into drug development and approvals, medical device development and approvals, post-market surveillance, market access and reimbursement/coverage decision making, and clinical & regulatory decision making. The drug development and approval segment dominated the RWE solutions market owing to increasing number of clinical trials specifically in the field of oncology and cardiovascular therapeutics. The drug development and approvals segment is further sub-segmented into oncology, cardiovascular disease, neurology, immunology, and other therapeutic areas. Cardiovascular disease segment is expected to witness fastest growth rate during the forecast period owing to increasing prevalence of CVDs and growing development of cardiovascular registries.

"Pharmaceutical and medical device companies are expected to witnessing fastest growth during the forecast period"

Based on end users, the RWE solutions market is segmented into pharmaceutical & medical device companies, healthcare providers, healthcare payers, and other end users. The pharmaceutical & medical device companies segment are expected to witness the fastest growth rate through 2027. Pharmaceutical companies require data describing both the approved and medically accepted alternative uses of previously approved drugs. Increasing growth in investments on pharmaceutical and medical device R&D and growing number of approvals are driving the use of RWE solutions in this segment. Additionally, the use of RWE solutions in meeting regulatory compliances is increasing along with payer demands related to HEOR, which are also the key factors supporting the growth of RWE solutions market.

"North America leads the RWE solutions market by region"

North America accounted for the largest share of the global RWE solutions market. Majority of established players are based in North America. Furthermore, rising geriatric population is contributing to increase in chronic disease in the region, which is driving the demand for new drugs and medical devices, thereby catering to an increasing demand for evidence generation during clinical trials and post-market surveillance activities. The Asia Pacific market is projected to register the highest CAGR during the forecast period. Market growth in the Asia Pacific is attributed to the increasing government initiatives for the adoption of RWE studies.

The break-down of primary participants is as mentioned below:

  • By Company Type - Tier 1: 40%, Tier 2: 35%, and Tier 3: 25%
  • By Designation - C-level: 35%, Director-level: 45%, and Others: 20%
  • By Region - North America: 55%, Europe: 20%, Asia Pacific: 15%, Latin America: 5%, and Middle East and Africa : 5%.

Key players in the RWE Solutions Market

The key players operating in the RWE solutions market include IQVIA Holdings Inc. (US), IBM Corporation (US), OPTUM Inc. (US), Icon Plc (Ireland), Syneos Health Inc. (US), Parexel International Corporation (US).

Research Coverage:

The report analyzes the RWE Solutions market and aims at estimating the market size and future growth potential of various market segments, based on component, applications, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, solution offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

  • Market Penetration: Comprehensive information on the solution portfolios of the top players in the RWE solutions market. The report analyzes this market by component, application, end user, and region.
  • Market Development: Comprehensive information on the lucrative emerging markets, by component, application, end user, and region
  • Market Diversification: Exhaustive information about the solution portfolios, growing geographies, recent developments, and investments in the RWE solutions market
  • Competitive Assessment: In-depth assessment of market ranking, growth strategies, solution offerings, and capabilities of the leading players in the RWE solutions market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
    • 1.2.2 MARKETS COVERED
    • 1.2.3 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
    • TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • 1.4 LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Insights from primary experts
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION: RWE SOLUTIONS MARKET
    • FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 6 MARKET SIZE ESTIMATION: SEGMENTAL EXTRAPOLATION
    • FIGURE 7 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • FIGURE 8 CAGR PROJECTIONS: OVERALL RWE SOLUTIONS MARKET
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET RANKING ANALYSIS
  • 2.5 ASSUMPTIONS FOR THE STUDY
  • 2.6 RISK ASSESSMENT
    • TABLE 2 RISK ASSESSMENT: RWE SOLUTIONS MARKET
  • 2.7 LIMITATIONS
    • 2.7.1 METHODOLOGY-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

    • FIGURE 10 RWE SOLUTIONS MARKET, BY COMPONENT, 2022 VS. 2027 (USD MILLION)
    • FIGURE 11 DATA SETS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 12 DISPARATE DATA SETS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 13 RWE SOLUTIONS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 14 RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 15 RWE SOLUTIONS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 16 RWE SOLUTIONS MARKET: GEOGRAPHIC SNAPSHOT

4 PREMIUM INSIGHTS

  • 4.1 RWE SOLUTIONS MARKET OVERVIEW
    • FIGURE 17 SUPPORT FROM REGULATORY BODIES FOR THE USE OF RWE SOLUTIONS IS A MAJOR FACTOR DRIVING THE MARKET GROWTH
  • 4.2 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY END USER AND COUNTRY (2021)
    • FIGURE 18 JAPAN ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021
  • 4.3 RWE SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 19 CHINA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • 4.4 REGIONAL MIX: RWE SOLUTIONS MARKET (2022-2027)
    • FIGURE 20 NORTH AMERICA WILL CONTINUE TO DOMINATE THE RWE SOLUTIONS MARKET DURING THE FORECAST PERIOD
  • 4.5 RWE SOLUTIONS MARKET: DEVELOPED VS. EMERGING MARKETS
    • FIGURE 21 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 22 RWE SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 3 MARKET DYNAMICS: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rise in the geriatric population and the subsequent increase in the prevalence of chronic diseases
      • 5.2.1.2 Shift from volume- to value-based care
      • 5.2.1.3 Potential of RWE in reducing drug development costs and expediting the drug development process
      • 5.2.1.4 Increased R&D spending for the development of new pharmaceutical products and medical devices
    • FIGURE 23 NUMBER OF CLINICAL TRIALS STARTED DURING 2015-2020
      • 5.2.1.5 Support from regulatory bodies for the use of RWE solutions
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Reluctance of medical practitioners and researchers to rely on real-world studies
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growth opportunities in emerging markets
      • 5.2.3.2 Rise in focus on end-to-end RWE services
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Lack of universally accepted methodology standards and data processing infrastructure
      • 5.2.4.2 Shortage of skilled professionals

6 INDUSTRY INSIGHTS

  • 6.1 INDUSTRY TRENDS
    • 6.1.1 EMERGING ROLE OF WEARABLE DEVICES
    • FIGURE 24 UTILIZATION OF WEARABLES IN CLINICAL TRIALS, BY THERAPEUTIC AREA, 2019
    • 6.1.2 SOCIAL MEDIA-SOURCED RWE
    • 6.1.3 RISE IN THE USE OF RWD AND RWE ACROSS THE PHARMACEUTICAL INDUSTRY
    • FIGURE 25 RECOMMENDED INVESTMENT MODEL FOR RWD AND RWE
    • 6.1.4 INTERNAL VS. OUTSOURCED RWE ANALYTICS APPROACH
    • FIGURE 26 INTERNAL VS. OUTSOURCED RWE ANALYTICS APPROACH
    • 6.1.5 INCORPORATION OF ARTIFICIAL INTELLIGENCE IN RWD MANAGEMENT
  • 6.2 REAL-WORLD DATA SOURCES
    • TABLE 4 INDICATIVE LIST OF NATIONAL DATABASES IN DEVELOPED COUNTRIES
  • 6.3 ECOSYSTEM ANALYSIS
    • FIGURE 27 ECOSYSTEM COVERAGE: PARENT MARKET (HEALTHCARE IT SOLUTIONS)
    • FIGURE 28 ECOSYSTEM COVERAGE: RWE SOLUTIONS MARKET
  • 6.4 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 5 PORTER'S FIVE FORCES ANALYSIS
    • 6.4.1 THREAT OF NEW ENTRANTS
    • 6.4.2 BARGAINING POWER OF SUPPLIERS
    • 6.4.3 BARGAINING POWER OF BUYERS
    • 6.4.4 THREAT OF SUBSTITUTES
    • 6.4.5 INTENSITY OF COMPETITIVE RIVALRY
  • 6.5 PRICING ANALYSIS
    • 6.5.1 AVERAGE SELLING PRICE
    • 6.5.2 HCIT EXPENDITURE/PRICING ANALYSIS
      • 6.5.2.1 North America
    • TABLE 6 NORTH AMERICA: HEALTHCARE EXPENDITURE, BY COUNTRY
      • 6.5.2.2 Europe
      • 6.5.2.3 Asia Pacific
    • TABLE 7 JAPAN: HEALTHCARE IT INITIATIVES AND FUNDING
  • 6.6 TECHNOLOGY ANALYSIS
  • 6.7 REGULATORY BODIES, GOVERNMENTS, AND OTHER ORGANIZATIONS
    • 6.7.1 NORTH AMERICA
      • 6.7.1.1 Case examples
    • 6.7.2 EUROPE
    • 6.7.3 ASIA PACIFIC
      • 6.7.3.1 China
      • 6.7.3.2 Japan
  • 6.8 PATENT ANALYSIS
    • 6.8.1 PATENT PUBLICATION TRENDS FOR RWE SOLUTIONS
    • FIGURE 29 GLOBAL PATENT PUBLICATION TRENDS IN THE RWE SOLUTIONS MARKET, 2016-2021
    • 6.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS
    • FIGURE 30 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR MEDICAL SIMULATION PATENTS (JANUARY 2011 TO JUNE 2021)
    • 6.8.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN THE RWE SOLUTIONS MARKET
    • FIGURE 31 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR RWE SOLUTIONS, 2016-2021
    • TABLE 8 LIST OF PATENTS IN THE RWE SOLUTIONS MARKET, 2019-2022
  • 6.9 KEY CONFERENCES AND EVENTS (2022-2023)
    • TABLE 9 RWE SOLUTIONS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
  • 6.10 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 6.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS
    • TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS
    • 6.10.2 BUYING CRITERIA
    • FIGURE 33 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS
    • TABLE 11 KEY BUYING CRITERIA FOR TOP 3 END USERS

7 RWE SOLUTIONS MARKET, BY COMPONENT

  • 7.1 INTRODUCTION
    • TABLE 12 RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
  • 7.2 SERVICES
    • 7.2.1 RISING NEED TO CONVERT DATA INTO ACTIONABLE EVIDENCE TO DRIVE DEMAND
    • TABLE 13 RWE SERVICES OFFERED BY KEY MARKET PLAYERS
    • TABLE 14 RWE SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.3 DATA SETS
    • TABLE 15 DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 16 DATA SETS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.3.1 DISPARATE DATA SETS
    • TABLE 17 DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 18 DISPARATE DATA SETS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
      • 7.3.1.1 Clinical settings data set
        • 7.3.1.1.1 Increasing utilization of EHR data for trial recruitment to fuel growth
    • FIGURE 34 ADOPTION OF EHR BY HOSPITAL SERVICE TYPE, 2019-2021
    • TABLE 19 CLINICAL SETTINGS DATA SETS OFFERED BY KEY MARKET PLAYERS
    • TABLE 20 CLINICAL SETTINGS DISPARATE DATA SETS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
      • 7.3.1.2 Claims data set
        • 7.3.1.2.1 Growing need to understand the economic benefits of drug reimbursement by payers to drive growth
    • TABLE 21 CLAIMS DATA SETS OFFERED BY KEY MARKET PLAYERS
    • TABLE 22 CLAIMS DISPARATE DATA SETS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
      • 7.3.1.3 Pharmacy data set
        • 7.3.1.3.1 Increasing adoption of e-prescribing systems to drive growth
    • FIGURE 35 TOTAL E-PRESCRIPTIONS AND CONTROLLED SUBSTANCE PRESCRIPTIONS IN THE US (2018-2021)
    • TABLE 23 PHARMACY DATA SETS OFFERED BY KEY MARKET PLAYERS
    • TABLE 24 PHARMACY DISPARATE DATA SET MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
      • 7.3.1.4 Patient-powered data set
        • 7.3.1.4.1 Increasing need to access opinions on diseases and treatments across social media to drive growth
    • TABLE 25 PATIENT-POWERED DATA SETS OFFERED BY KEY MARKET PLAYERS
    • TABLE 26 RWE PATIENT-POWERED DISPARATE DATA MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
      • 7.3.1.5 Registry-based data sets
        • 7.3.1.5.1 Increasing number of disease registries is driving the demand for registry-based data sets in evidence generation
    • TABLE 27 USE OF REGISTRIES FOR EVIDENCE GENERATION
    • TABLE 28 REGISTRY-BASED DATA SETS OFFERED BY KEY MARKET PLAYERS
    • TABLE 29 REGISTRY-BASED DISPARATE DATA SETS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.3.2 INTEGRATED DATA SETS
      • 7.3.2.1 Increasing demand for integrated data from multiple sources to drive growth
    • TABLE 30 INTEGRATED DATA SETS OFFERED BY KEY MARKET PLAYERS
    • TABLE 31 INTEGRATED DATA SETS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

8 RWE SOLUTIONS MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • FIGURE 36 NUMBER OF CLINICAL TRIALS (COMPLETED), BY CONDITION/DISEASE, SEPTEMBER 2022
    • TABLE 32 RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 8.2 DRUG DEVELOPMENT AND APPROVALS
    • TABLE 33 RWE SOLUTIONS MARKET IN DRUG DEVELOPMENT AND APPROVALS, BY TYPE 2020-2027 (USD MILLION)
    • 8.2.1 ONCOLOGY
      • 8.2.1.1 Growing number of clinical trials focused on cancer treatment to drive growth
    • TABLE 34 LIST OF PIPELINE DRUGS FOR ONCOLOGY (2018)
    • TABLE 35 DRUG DEVELOPMENT AND APPROVALS MARKET IN ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • 8.2.2 CARDIOVASCULAR DISEASE
      • 8.2.2.1 High prevalence of CVD to drive growth
    • TABLE 36 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASE (BY FEBRUARY 2022)
    • TABLE 37 DRUG DEVELOPMENT AND APPROVALS MARKET IN CARDIOVASCULAR DISEASE, BY COUNTRY, 2020-2027 (USD MILLION)
    • 8.2.3 NEUROLOGY
      • 8.2.3.1 Growing prevalence of neurological disorders to drive growth
    • TABLE 38 DRUG DEVELOPMENT AND APPROVALS MARKET IN NEUROLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • 8.2.4 IMMUNOLOGY
      • 8.2.4.1 Increasing focus on developing innovative products to drive growth
    • TABLE 39 DRUG DEVELOPMENT AND APPROVALS MARKET IN IMMUNOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • 8.2.5 OTHER THERAPEUTIC AREAS
    • TABLE 40 DRUG DEVELOPMENT AND APPROVALS MARKET IN OTHER THERAPEUTIC AREAS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.3 MEDICAL DEVICE DEVELOPMENT AND APPROVALS
    • 8.3.1 INCREASING RESEARCH IN MEDICAL DEVICE DEVELOPMENT TO DRIVE DEMAND
    • TABLE 41 RWE SOLUTIONS MARKET IN MEDICAL DEVICE DEVELOPMENT AND APPROVALS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.4 POST-MARKET SURVEILLANCE
    • 8.4.1 EMR AND PRODUCT/PATIENT REGISTRIES HAVE BECOME KEY DATA SOURCES FOR GENERATING EVIDENCE IN POST-MARKET SURVEILLANCE
    • TABLE 42 RWE SOLUTIONS MARKET IN POST-MARKET SURVEILLANCE, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.5 MARKET ACCESS AND REIMBURSEMENT/COVERAGE DECISION MAKING
    • 8.5.1 GROWING USE OF RWE SOLUTIONS TO DEVELOP ECONOMIC AND BUDGET IMPACT MODELS
    • TABLE 43 RWE SOLUTIONS MARKET IN MARKET ACCESS AND REIMBURSEMENT/COVERAGE DECISION MAKING, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.6 CLINICAL AND REGULATORY DECISION MAKING
    • 8.6.1 LIMITED VALIDITY OF RANDOMIZED CONTROLLED TRIALS DRIVING THE USE OF RWE SOLUTIONS IN THE SEGMENT
    • TABLE 44 RWE SOLUTIONS MARKET IN CLINICAL AND REGULATORY DECISION MAKING, BY COUNTRY, 2020-2027 (USD MILLION)

9 RWE SOLUTIONS MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 45 RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.2 PHARMACEUTICAL & MEDICAL DEVICE COMPANIES
    • 9.2.1 INCREASED R&D EXPENDITURE IN INNOVATIVE MEDICINES TO DRIVE MARKET GROWTH
    • FIGURE 37 FDA PHASE TRANSITION SUCCESS RATES, 2011-2020
    • FIGURE 38 ANNUAL DRUG APPROVALS BY CDER (FDA), 2011-2021
    • FIGURE 39 R&D SPENDING OF PHARMA MEMBER COMPANIES, 2011-2020
    • TABLE 46 RWE SOLUTIONS MARKET FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.3 HEALTHCARE PAYERS
    • 9.3.1 INCREASED FOCUS ON OUTCOME-BASED PAYMENT MODELS TO DRIVE DEMAND
    • TABLE 47 RWE SOLUTIONS MARKET FOR HEALTHCARE PAYERS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.4 HEALTHCARE PROVIDERS
    • 9.4.1 RISE IN THE NEED TO IMPROVE THE PROFITABILITY OF HEALTHCARE PROVIDERS TO BOOST USE
    • TABLE 48 RWE SOLUTIONS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.5 OTHER END USERS
    • TABLE 49 RWE SOLUTIONS MARKET FOR OTHER END USERS, BY COUNTRY, 2020-2027 (USD MILLION)

10 RWE SOLUTIONS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 50 RWE SOLUTIONS MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 40 NORTH AMERICA: RWE SOLUTIONS MARKET SNAPSHOT
    • TABLE 51 NORTH AMERICA: RWE SOLUTIONS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 52 NORTH AMERICA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
    • TABLE 53 NORTH AMERICA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 54 NORTH AMERICA: DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 55 NORTH AMERICA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 56 NORTH AMERICA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 57 NORTH AMERICA: RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 The US accounted for the largest share of the North American market
    • TABLE 58 US: MACROECONOMIC INDICATORS
    • TABLE 59 US: RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
    • TABLE 60 US: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 61 US: DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 62 US: RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 63 US: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 64 US: RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Growing number of clinical trials in Canada to drive market growth
    • TABLE 65 CANADA: MACROECONOMIC INDICATORS
    • TABLE 66 CANADA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
    • TABLE 67 CANADA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 68 CANADA: DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 69 CANADA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 70 CANADA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 71 CANADA: RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 72 EUROPE: RWE SOLUTIONS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 73 EUROPE: RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
    • TABLE 74 EUROPE: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 75 EUROPE: DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 76 EUROPE: RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 77 EUROPE: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 78 EUROPE: RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 High pharmaceutical R&D spending in Germany to boost the market growth
    • TABLE 79 GERMANY: MACROECONOMIC INDICATORS
    • TABLE 80 GERMANY: RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
    • TABLE 81 GERMANY: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 82 GERMANY: DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 83 GERMANY: RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 84 GERMANY: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 85 GERMANY: RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 The growing adoption of HTA in the UK supports market growth
    • TABLE 86 UK: MACROECONOMIC INDICATORS
    • TABLE 87 UK: RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
    • TABLE 88 UK: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 89 UK: DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 90 UK: RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 91 UK: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 92 UK: RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 High number of oncology clinical trials in France to drive market growth
    • TABLE 93 FRANCE: MACROECONOMIC INDICATORS
    • TABLE 94 FRANCE: RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
    • TABLE 95 FRANCE: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 96 FRANCE: DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 97 FRANCE: RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 98 FRANCE: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 99 FRANCE: RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.4 ITALY
      • 10.3.4.1 The demand for RWE in Italy is high due to the widespread use of pay-for-outcomes
    • TABLE 100 ITALY: MACROECONOMIC INDICATORS
    • TABLE 101 ITALY: RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
    • TABLE 102 ITALY: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 103 ITALY: DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 104 ITALY: RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 105 ITALY: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 106 ITALY: RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.5 SPAIN
      • 10.3.5.1 Rising R&D expenditure to propel market growth in Spain
    • TABLE 107 SPAIN: MACROECONOMIC INDICATORS
    • TABLE 108 SPAIN: RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
    • TABLE 109 SPAIN: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 110 SPAIN: DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 111 SPAIN: RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 112 SPAIN: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 113 SPAIN: RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.6 REST OF EUROPE
    • TABLE 114 REST OF EUROPE: RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
    • TABLE 115 REST OF EUROPE: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 116 REST OF EUROPE: DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 117 REST OF EUROPE: RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 118 REST OF EUROPE: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 119 REST OF EUROPE: RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 41 ASIA PACIFIC: RWE SOLUTIONS MARKET SNAPSHOT
    • TABLE 120 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 121 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
    • TABLE 122 ASIA PACIFIC: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 123 ASIA PACIFIC: DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 124 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 125 ASIA PACIFIC: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 126 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.1 JAPAN
      • 10.4.1.1 Stringent regulatory scenario in Japan to restrain market growth
    • TABLE 127 JAPAN: MACROECONOMIC INDICATORS
    • TABLE 128 JAPAN: RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
    • TABLE 129 JAPAN: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 130 JAPAN: DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 131 JAPAN: RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 132 JAPAN: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 133 JAPAN: RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 Low cost of clinical trials and large pharmaceutical R&D base in China to drive market growth
    • TABLE 134 CHINA: MACROECONOMIC INDICATORS
    • TABLE 135 CHINA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
    • TABLE 136 CHINA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 137 CHINA: DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 138 CHINA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 139 CHINA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 140 CHINA: RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Growing adoption of outcomes-based research among pharmaceutical and medical device manufacturers in India to drive market growth
    • TABLE 141 INDIA: MACROECONOMIC INDICATORS
    • TABLE 142 INDIA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
    • TABLE 143 INDIA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 144 INDIA: DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 145 INDIA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 146 INDIA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 147 INDIA: RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.4 REST OF ASIA PACIFIC
    • TABLE 148 REST OF ASIA PACIFIC: RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
    • TABLE 149 REST OF ASIA PACIFIC: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 150 REST OF ASIA PACIFIC: DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 151 REST OF ASIA PACIFIC: RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 152 REST OF ASIA PACIFIC: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 153 REST OF ASIA PACIFIC: RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 INCREASED HEALTHCARE EXPENDITURE TO SUPPORT MARKET GROWTH
    • TABLE 154 LATIN AMERICA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
    • TABLE 155 LATIN AMERICA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 156 LATIN AMERICA: DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 157 LATIN AMERICA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 158 LATIN AMERICA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 159 LATIN AMERICA: RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 GROWING AVAILABILITY OF HEALTHCARE FUNDING IN THE MIDDLE EAST OFFERS OPPORTUNITIES FOR MARKET GROWTH
    • TABLE 160 MIDDLES EAST & AFRICA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020-2027 (USD MILLION)
    • TABLE 161 MIDDLES EAST & AFRICA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 162 MIDDLES EAST & AFRICA: DISPARATE DATA SETS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 163 MIDDLES EAST & AFRICA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 164 MIDDLES EAST & AFRICA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 165 MIDDLES EAST & AFRICA: RWE SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 STRATEGIES ADOPTED BY KEY PLAYERS /RIGHT TO WIN
    • TABLE 166 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE RWE SOLUTIONS MARKET
  • 11.3 REVENUE SHARE ANALYSIS OF KEY PLAYERS
    • FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN THE RWE SOLUTIONS MARKET
  • 11.4 MARKET RANKING ANALYSIS
    • FIGURE 43 RWE SOLUTIONS MARKET RANKING, BY KEY PLAYER, 2021
  • 11.5 COMPETITIVE BENCHMARKING
    • TABLE 167 RWE SOLUTIONS MARKET: DETAILED LIST OF SMALL & MEDIUM PLAYERS
  • 11.6 COMPANY FOOTPRINT
    • 11.6.1 END-USER FOOTPRINT OF COMPANIES
    • 11.6.2 PRODUCT FOOTPRINT OF COMPANIES
    • 11.6.3 REGIONAL FOOTPRINT OF COMPANIES
  • 11.7 COMPANY EVALUATION QUADRANT
    • 11.7.1 STARS
    • 11.7.2 EMERGING LEADERS
    • 11.7.3 PERVASIVE PLAYERS
    • 11.7.4 PARTICIPANTS
    • FIGURE 44 RWE SOLUTIONS MARKET: COMPANY EVALUATION QUADRANT (2021)
  • 11.8 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES
    • 11.8.1 PROGRESSIVE COMPANIES
    • 11.8.2 STARTING BLOCKS
    • 11.8.3 RESPONSIVE COMPANIES
    • 11.8.4 DYNAMIC COMPANIES
    • FIGURE 45 START-UP/SME EVALUATION QUADRANT (2021)
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 FDA APPROVALS/SERVICE ENHANCEMENTS
    • TABLE 168 FDA APPROVALS/ENHANCEMENTS, 2019-2022
    • 11.9.2 DEALS
    • TABLE 169 DEALS, 2019-2022
    • 11.9.3 OTHER DEVELOPMENTS
    • TABLE 170 OTHER DEVELOPMENTS, 2019-2022

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products, Recent Developments, MnM View)**
    • 12.1.1 IQVIA HOLDINGS INC.
    • TABLE 171 IQVIA HOLDINGS INC.: BUSINESS OVERVIEW
    • FIGURE 46 IQVIA HOLDINGS INC: COMPANY SNAPSHOT (2021)
    • 12.1.2 IBM CORPORATION (IBM)
    • TABLE 172 IBM CORPORATION: BUSINESS OVERVIEW
    • FIGURE 47 IBM CORPORATION: COMPANY SNAPSHOT (2021)
    • 12.1.3 OPTUM INC. (A SUBSIDIARY OF THE UNITED HEALTH GROUP, INC.)
    • TABLE 173 OPTUM INC.: BUSINESS OVERVIEW
    • FIGURE 48 OPTUM INC.: COMPANY SNAPSHOT (2021)
    • 12.1.4 ICON PLC.
    • TABLE 174 ICON PLC.: BUSINESS OVERVIEW
    • FIGURE 49 ICON PLC.: COMPANY SNAPSHOT (2021)
    • 12.1.5 SYNEOS HEALTH, INC.
    • TABLE 175 SYNEOS HEALTH INC.: BUSINESS OVERVIEW
    • FIGURE 50 SYNEOS HEALTH INC.: COMPANY SNAPSHOT (2021)
    • 12.1.6 PAREXEL INTERNATIONAL CORPORATION
    • TABLE 176 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW
    • 12.1.7 THERMO FISHER SCIENTIFIC INC.
    • TABLE 177 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
    • FIGURE 51 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.8 LABCORP HOLDINGS
    • TABLE 178 LABCORP HOLDINGS: BUSINESS OVERVIEW
    • FIGURE 52 LABCORP HOLDINGS: COMPANY SNAPSHOT (2021)
    • 12.1.9 ORACLE CORPORATION
    • TABLE 179 ORACLE CORPORATION: BUSINESS OVERVIEW
    • FIGURE 53 ORACLE CORPORATION: COMPANY SNAPSHOT (2021)
    • 12.1.10 ELEVANCE HEALTH
    • TABLE 180 ELEVANCE HEALTH: BUSINESS OVERVIEW
    • FIGURE 54 ELEVANCE HEALTH: COMPANY SNAPSHOT (2021)
    • 12.1.11 SAS INSTITUTE
    • TABLE 181 SAS INSTITUTE: BUSINESS OVERVIEW
    • FIGURE 55 SAS INSTITUTE: COMPANY SNAPSHOT (2021)
    • 12.1.12 AETION INC.
    • TABLE 182 AETION INC.: BUSINESS OVERVIEW
    • 12.1.13 TRINETX LLC
    • TABLE 183 TRINETX LLC: BUSINESS OVERVIEW
    • 12.1.14 TRINITY LIFE SCIENCES
    • TABLE 184 TRINITY LIFE SCIENCES: BUSINESS OVERVIEW
    • 12.1.15 PERKINELMER INC.
    • TABLE 185 PERKINELMER INC.: BUSINESS OVERVIEW
    • FIGURE 56 PERKINELMER INC.: COMPANY SNAPSHOT (2021)
    • 12.1.16 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION
    • TABLE 186 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: BUSINESS OVERVIEW
    • FIGURE 57 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: COMPANY SNAPSHOT (2021)
    • 12.1.17 CLINIGEN
    • TABLE 187 CLINIGEN: BUSINESS OVERVIEW
    • FIGURE 58 CLINIGEN: COMPANY SNAPSHOT (2021)
    • 12.1.18 CEGEDIM HEALTH DATA
    • TABLE 188 CEGEDIM HEALTH DATA: BUSINESS OVERVIEW
    • FIGURE 59 CEGEDIM HEALTH DATA: COMPANY SNAPSHOT (2021)
    • 12.1.19 VERANTOS INC.
    • TABLE 189 VERANTOS INC.: BUSINESS OVERVIEW
    • 12.1.20 MEDPACE HOLDINGS INC.
    • TABLE 190 MEDPACE HOLDINGS INC.: BUSINESS OVERVIEW
    • FIGURE 60 MEDPCE HOLDINGS INC.: COMPANY SNAPSHOT (2021)
  • *Details on Business Overview, Products, Recent Developments, MnM View might not be captured in case of unlisted companies.
  • 12.2 OTHER PLAYERS
    • 12.2.1 HEALTHVERITY INC.
    • 12.2.2 DATAVANT
    • 12.2.3 SYAPSE INC.
    • 12.2.4 TEMPUS LABS INC.
    • 12.2.5 FLATIRON HEALTH

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제